PLIANT THERAPEUTICS, INC. Long-Term Debt, Maturity, after Year Five
PLIANT THERAPEUTICS, INC. (PLRX) had Long-Term Debt, Maturity, after Year Five of $0 as of 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2025-03-03
- 2024-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
- 2022-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |